A Phase 2 interventional study of Placebo to Ertuglilflozin 1 or 5 mg and Ertugliflozin 1 mg in Diabetes Mellitus, Type 2 and Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-09-13.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 12th largest by enrollment, is one of 5 that started in 2010, is one of 3 in phase 2, and was the 4th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Amsterdam UMC, location VUmc · Sites in United States, Netherlands
Ages 18–85
Baylor Research Institute · Sites in United States
Ages 18–84
Shanghai Zhongshan Hospital · Sites in China
Ages 19+
By country, each count listing its studies:
ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 194 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 83 across the 28 interventional studies. Of the 24 that completed or were terminated, 19 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 85th largest by enrollment of the 170 interventional ones that give a count, is one of 16 that started in 2010, is one of 21 in phase 2, and was the 103rd registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
MK-8835-042 (B1521004) is designed to assess the safety and efficacy of an investigational drug, ertugliflozin (MK-8835, PF-04971729), in participants with type 2 diabetes and hypertension. Participants in the study will receive 1 of 5 treatments for 28 days (either placebo, 1 of 3 doses of ertugliflozin [1, 5, or 25 mg], or the approved drug hydrochlorothiazide [HCTZ]). The primary hypothesis of the study was that ertugliflozin was superior to placebo on the change from baseline in average, 24-hour systolic blood pressure (SBP) on Day 28.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Placebo to ertugliflozin (resembling either 1 mg or 5 mg), placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days.
Drug: Placebo to Ertuglilflozin 1 or 5 mg · Drug: Placebo to HCTZ · Drug: Placebo to ertuglilflozin 25 mg
Ertugliflozin 1 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days
Drug: Ertugliflozin 1 mg · Drug: Placebo to HCTZ · Drug: Placebo to ertuglilflozin 25 mg
Ertugliflozin 5 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days
Drug: Ertugliflozin 5 mg · Drug: Placebo to HCTZ · Drug: Placebo to ertuglilflozin 25 mg
Ertugliflozin 25 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to HCTZ once daily for 28 days
Drug: Placebo to Ertuglilflozin 1 or 5 mg · Drug: Ertugliflozin 25 mg · Drug: Placebo to HCTZ
HCTZ 12.5 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to ertugliflozin (resembling 25 mg) once daily for 28 days
Drug: Placebo to Ertuglilflozin 1 or 5 mg · Drug: HCTZ 12.5mg · Drug: Placebo to ertuglilflozin 25 mg
Placebo to ertuglilflozin tablet 1 or 5 mg once daily for 28 days
Ertugliflozin tablet 1 mg once daily for 28 days
Ertugliflozin tablet 5 mg once daily for 28 days
Ertugliflozin tablet 25 mg once daily for 28 days
Hydrocholorthiazide (HCTZ) 12.5 mg capsule once daily for 28 days
Placebo to HCTZ 12.5 mg capsule once daily for 28 days
Placebo to ertuglilflozin tablet 25 mg once daily for 28 days
Baseline 24-hour Average Systolic Blood Pressure (SBP)
Baseline 24-hour average SBP was assessed using 24-hour ambulatory blood pressure monitoring (ABPM).
Time frame: 24 hours
Change From Baseline on 24-hour Average SBP at Week 4
Change from baseline on 24-hour average SBP at Week 4 assessed using 24-hour ABPM. In the case of missing data, last observation carried forward (LOCF).
Time frame: Baseline and Week 4
Baseline Average Daytime and Nighttime SBP
Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.
Time frame: Daytime: 16 hours; Nighttime: 8 hours
Change From Baseline on Daytime Average SBP at Week 4
Change from baseline on daytime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.
Time frame: Baseline and Week 4
Change From Baseline on Nighttime Average SBP at Week 4
Change from baseline on nighttime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.
Time frame: Baseline and Week 4
Baseline Seated, Triplicate Trough SBP
Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough SBP is calculated as the mean of triplicate (3) trough SBP measures.
Time frame: Baseline
Change From Baseline in Seated, Triplicate Trough SBP at Week 4
Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.
Time frame: Baseline and Week 4
Baseline 24-hour, Daytime and Nightime Average Diastolic Blood Pressure (DBP)
Baseline 24-hour average DBP was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.
Time frame: up to 24 hours
Change From Baseline on 24-hour Average DBP at Week 4
Change from baseline on 24-hour average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF.
Time frame: Baseline and Week 4
Change From Baseline on Daytime Average DBP at Week 4
Change from baseline on daytime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.
Time frame: Baseline and Week 4
Change From Baseline on Nighttime Average DBP at Week 4
Change from baseline on nighttime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.
Time frame: Baseline and Week 4
Baseline Seated, Triplicate Trough DBP
Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough DBP is calculated as the mean of triplicate (3) trough DBP measures.
Time frame: Baseline
Change From Baseline in Seated, Triplicate Trough DBP at Week 4
Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.
Time frame: Baseline and Week 4
Baseline 24-hour, Daytime and Nightime Average Heart Rate
Baseline 24-hour average heart rate was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.
Time frame: up to 24 hours
Change From Baseline on 24-hour Average Heart Rate at Week 4
Change from baseline in 24-hour average heart rate at Week 4 using 24 hour ABPM.
Time frame: Baseline and Week 4
Change From Baseline on Daytime Average Heart Rate at Week 4
Change from baseline in daytime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.
Time frame: Baseline and Week 4
Change From Baseline on Nighttime Average Heart Rate at Week 4
Change from baseline in 24-hour nighttime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.
Time frame: Baseline and Week 4
Baseline Seated, Triplicate Trough Heart Rate
Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. Baseline trough heart rate is calculated as the mean of triplicate (3) trough heart rate measures.
Time frame: Baseline
Change From Baseline in Seated, Triplicate Trough Heart Rate at Week 4
Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.
Time frame: Baseline and Week 4
Baseline 24-hour Average Urinary Glucose Excretion
Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as \>20 hours and \<28 hours).
Time frame: 24 hours
Change From Baseline on 24-hour Urinary Glucose Excretion at Week 4
Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as \>20 hours and \<28 hours). In the case of missing data, LOCF.
Time frame: Baseline and Week 4
Baseline Fasting Plasma Glucose (FPG)
For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).
Time frame: Baseline
Change From Baseline in FPG at Week 4
For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).
Time frame: Baseline and Week 4
Change From Baseline in FPG at Week 2
For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).
Time frame: Baseline and Week 2
Number of Participants Who Experienced an Adverse Event (AE)
An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug.
Time frame: Up to 63 days (including run-in, treatment period, and follow-up)
Number of Participants Who Discontinued Study Drug Due to an AE
An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug. Discontinuation of study drug due to an AE includes temporary and permanent discontinuation of study drug due to an AE.
Time frame: Up to 28 days (treatment period)
| Milestone | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Started | 39 | 39 | 38 | 39 | 39 |
| Treated | 38 | 39 | 38 | 39 | 39 |
| Completed | 36 | 37 | 36 | 36 | 39 |
| Not completed | 3 | 2 | 2 | 3 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Reason not available | 0 | 1 | 1 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Not treated | 1 | 0 | 0 | 0 | 0 |
Baseline 24-hour average SBP was assessed using 24-hour ambulatory blood pressure monitoring (ABPM).
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Baseline 24-hour Average Systolic Blood Pressure (SBP) | 136.11 ± 15.298 | 133.13 ± 10.868 | 135.08 ± 12.073 | 135.59 ± 11.929 | 139.55 ± 11.941 |
Change from baseline on 24-hour average SBP at Week 4 assessed using 24-hour ABPM. In the case of missing data, last observation carried forward (LOCF).
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Change From Baseline on 24-hour Average SBP at Week 4 | 0.26 (-1.31 to 1.70) | -2.71 (-4.15 to -1.33) | -3.73 (-5.30 to -2.18) | -3.42 (-4.86 to -1.99) | -2.95 (-4.39 to -1.51) |
Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Daytime | 139.95 ± 15.107 | 136.85 ± 11.361 | 138.89 ± 11.724 | 139.56 ± 12.343 | 143.32 ± 12.637 |
| Nighttime | 127.54 ± 16.858 | 125.15 ± 12.180 | 126.37 ± 13.956 | 127.13 ± 13.553 | 131.68 ± 12.912 |
Change from baseline on daytime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Change From Baseline on Daytime Average SBP at Week 4 | 0.82 (-0.90 to 2.34) | -2.88 (-4.49 to -1.44) | -3.61 (-5.30 to -1.94) | -4.17 (-5.72 to -2.63) | -3.10 (-4.66 to -1.57) |
Change from baseline on nighttime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Change From Baseline on Nighttime Average SBP at Week 4 | -0.29 (-2.28 to 1.71) | -2.48 (-4.33 to -0.60) | -3.47 (-5.53 to -1.39) | -2.31 (-4.21 to -0.40) | -2.30 (-4.20 to -0.40) |
Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough SBP is calculated as the mean of triplicate (3) trough SBP measures.
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Baseline Seated, Triplicate Trough SBP | 135.17 ± 14.183 | 134.23 ± 13.631 | 137.31 ± 14.834 | 135.25 ± 13.452 | 138.07 ± 12.958 |
Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Change From Baseline in Seated, Triplicate Trough SBP at Week 4 | 1.24 (-0.93 to 3.41) | -2.77 (-4.95 to -0.60) | -5.92 (-8.12 to -3.73) | -4.96 (-7.15 to -2.77) | -3.13 (-5.26 to -1.00) |
Baseline 24-hour average DBP was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| 24-hr | 81.89 ± 9.655 | 78.67 ± 8.600 | 80.18 ± 8.655 | 80.36 ± 8.650 | 82.66 ± 9.459 |
| Daytime | 85.32 ± 10.127 | 81.77 ± 8.925 | 83.47 ± 9.164 | 83.59 ± 9.295 | 85.87 ± 9.884 |
| Nighttime | 74.24 ± 9.717 | 72.05 ± 9.330 | 73.05 ± 9.034 | 73.28 ± 8.760 | 75.76 ± 10.042 |
Change from baseline on 24-hour average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF.
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Change From Baseline on 24-hour Average DBP at Week 4 | 0.77 (-0.25 to 1.75) | -1.89 (-2.81 to -0.95) | -2.34 (-3.37 to -1.31) | -1.50 (-2.45 to -0.55) | -1.42 (-2.37 to -0.48) |
Change from baseline on daytime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Change From Baseline on Daytime Average DBP at Week 4 | 0.87 (-0.24 to 1.85) | -2.12 (-3.13 to -1.18) | -1.88 (-2.96 to -0.80) | -1.77 (-2.77 to -0.78) | -1.69 (-2.67 to -0.70) |
Change from baseline on nighttime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Change From Baseline on Nighttime Average DBP at Week 4 | 1.02 (-0.39 to 2.44) | -1.48 (-2.78 to -0.15) | -2.52 (-3.98 to -1.06) | -0.84 (-2.19 to 0.51) | -0.55 (-1.95 to 0.71) |
Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough DBP is calculated as the mean of triplicate (3) trough DBP measures.
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Baseline Seated, Triplicate Trough DBP | 84.89 ± 9.462 | 83.08 ± 7.557 | 83.79 ± 7.904 | 83.89 ± 8.290 | 84.72 ± 8.043 |
Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Change From Baseline in Seated, Triplicate Trough DBP at Week 4 | 0.30 (-0.97 to 1.58) | -0.90 (-2.18 to 0.37) | -0.75 (-2.03 to 0.54) | -2.71 (-4.00 to -1.43) | -2.54 (-3.79 to -1.29) |
Baseline 24-hour average heart rate was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.
| beats per minute | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| 24-hr | 81.11 ± 9.486 | 80.74 ± 6.950 | 79.68 ± 10.081 | 79.41 ± 9.063 | 79.08 ± 9.216 |
| Daytime | 84.43 ± 9.743 | 83.74 ± 7.044 | 82.71 ± 10.405 | 82.18 ± 9.136 | 81.95 ± 9.470 |
| Nighttime | 74.05 ± 9.871 | 74.44 ± 8.133 | 73.16 ± 10.205 | 73.49 ± 10.034 | 73.03 ± 9.736 |
Change from baseline in 24-hour average heart rate at Week 4 using 24 hour ABPM.
| Beats per minute | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Change From Baseline on 24-hour Average Heart Rate at Week 4 | 1.00 (-0.21 to 2.16) | -1.22 (-2.45 to -0.25) | 1.07 (-0.16 to 2.29) | -1.39 (-2.52 to -0.26) | -0.56 (-1.68 to 0.56) |
Change from baseline in daytime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.
| Beats per minute | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Change From Baseline on Daytime Average Heart Rate at Week 4 | 1.58 (0.25 to 2.83) | -1.80 (-3.09 to -0.70) | 1.10 (-0.24 to 2.43) | -1.07 (-2.31 to 0.15) | -0.06 (-1.22 to 1.22) |
Change from baseline in 24-hour nighttime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.
| Beats per minute | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Change From Baseline on Nighttime Average Heart Rate at Week 4 | -0.18 (-1.63 to 1.25) | -0.15 (-1.76 to 0.91) | 1.43 (-0.07 to 2.92) | -1.99 (-3.38 to -0.63) | -1.24 (-2.70 to 0.00) |
Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. Baseline trough heart rate is calculated as the mean of triplicate (3) trough heart rate measures.
| beats per minute | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Baseline Seated, Triplicate Trough Heart Rate | 77.07 ± 9.713 | 78.73 ± 8.446 | 77.30 ± 11.749 | 75.63 ± 9.550 | 77.97 ± 11.462 |
Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.
| beats per minute | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Change From Baseline in Seated, Triplicate Trough Heart Rate at Week 4 | 2.34 (0.85 to 3.82) | -1.86 (-3.35 to -0.38) | 1.22 (-0.28 to 2.71) | -1.51 (-3.01 to -0.01) | -0.99 (-2.44 to 0.46) |
Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as \>20 hours and \<28 hours).
| grams/day | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Baseline 24-hour Average Urinary Glucose Excretion | 13.35 ± 22.913 | 9.97 ± 20.085 | 8.04 ± 13.135 | 17.56 ± 29.101 | 6.96 ± 8.562 |
Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as \>20 hours and \<28 hours). In the case of missing data, LOCF.
| grams/day | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Change From Baseline on 24-hour Urinary Glucose Excretion at Week 4 | 4.15 (-3.50 to 11.81) | 46.33 (38.79 to 53.88) | 64.54 (56.77 to 72.31) | 74.49 (66.87 to 82.11) | -0.48 (-7.76 to 6.80) |
For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).
| mg/dL | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Baseline Fasting Plasma Glucose (FPG) | 169.47 ± 51.073 | 158.38 ± 40.806 | 158.29 ± 42.465 | 172.03 ± 55.878 | 156.87 ± 36.541 |
For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).
| mg/dL | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Change From Baseline in FPG at Week 4 | 4.39 (-2.16 to 10.94) | -13.70 (-20.35 to -7.06) | -30.41 (-37.12 to -23.71) | -31.03 (-37.74 to -24.32) | 3.79 (-2.74 to 10.31) |
For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).
| mg/dL | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Change From Baseline in FPG at Week 2 | -5.44 (-11.93 to 1.04) | -10.98 (-17.69 to -4.26) | -22.45 (-29.23 to -15.67) | -32.03 (-38.66 to -25.40) | 3.21 (-3.32 to 9.74) |
An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug.
| Participants | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 9 | 8 | 15 | 12 | 10 |
An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug. Discontinuation of study drug due to an AE includes temporary and permanent discontinuation of study drug due to an AE.
| Participants | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg |
|---|---|---|---|---|---|
| Number of Participants Who Discontinued Study Drug Due to an AE | 0 | 0 | 0 | 1 | 0 |
Collected over Up to 63 days (including screening and run-in [pre-randomization], treatment period, and follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/38 (2.6%) | 3/38 (7.9%) |
| Ertugliflozin 1 mg | — | 0/39 (0%) | 4/39 (10.3%) |
| Ertugliflozin 5 mg | — | 0/38 (0%) | 8/38 (21.1%) |
| Ertugliflozin 25 mg | — | 0/39 (0%) | 6/39 (15.4%) |
| HCTZ 12.5mg | — | 0/39 (0%) | 6/39 (15.4%) |
| Pre-randomization | — | 1/194 (0.5%) | 10/193 (5.2%) |
| Event | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg | Pre-randomization |
|---|---|---|---|---|---|---|
| Extradural haematomaInjury, poisoning and procedural complications | 1/38 | 0/39 | 0/38 | 0/39 | 0/39 | 0/194 |
| Skull fractureInjury, poisoning and procedural complications | 1/38 | 0/39 | 0/38 | 0/39 | 0/39 | 0/194 |
| HematuriaGeneral disorders | 0/38 | 0/39 | 0/38 | 0/39 | 0/39 | 1/194 |
| Event | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg | Pre-randomization |
|---|---|---|---|---|---|---|
| Genital infection fungalInfections and infestations | 0/38 | 0/39 | 3/38 | 1/39 | 0/39 | 0/193 |
| NasopharyngitisInfections and infestations | 0/38 | 0/39 | 2/38 | 0/39 | 0/39 | 0/193 |
| Upper respiratory tract infectionInfections and infestations | 2/38 | 1/39 | 1/38 | 0/39 | 0/39 | 3/193 |
| Urinary tract infectionInfections and infestations | 1/38 | 1/39 | 2/38 | 1/39 | 0/39 | 1/193 |
| AthralgiaMusculoskeletal and connective tissue disorders | 0/38 | 0/39 | 2/38 | 0/39 | 0/39 | 2/193 |
| DizzinessNervous system disorders | 2/38 | 0/39 | 0/38 | 1/39 | 0/39 | 3/193 |
| FatigueGeneral disorders | 0/38 | 0/39 | 1/38 | 2/39 | 0/39 | 0/193 |
| PyrexiaGeneral disorders | 0/38 | 0/39 | 0/38 | 0/39 | 2/39 | 0/193 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/38 | 2/39 | 0/38 | 0/39 | 2/39 | 0/193 |
| HeadacheNervous system disorders | 0/38 | 0/39 | 1/38 | 0/39 | 2/39 | 4/193 |
Baseline analysis population includes participants who received at least 1 dose of blinded treatment regimen.
| Age, Customized(Participants) | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg | Total |
|---|---|---|---|---|---|---|
| <18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 44 years | 3 | 4 | 3 | 5 | 1 | 16 |
| Between 45 and 64 years | 34 | 34 | 32 | 34 | 34 | 168 |
| 65 years and older | 1 | 1 | 3 | 0 | 4 | 9 |
| Sex: Female, Male(Participants) | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 25 mg | HCTZ 12.5mg | Total |
|---|---|---|---|---|---|---|
| Female | 14 | 12 | 13 | 12 | 11 | 62 |
| Male | 24 | 27 | 25 | 27 | 28 | 131 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from May 2010 to primary completion in Feb 2011, 8 months.
Results were first posted in Dec 2017, 6 years 10 months after primary completion. A results delay was requested in Apr 2013.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 8 months is below that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ertugliflozin